{"id":11797,"date":"2022-09-07T11:31:03","date_gmt":"2022-09-07T09:31:03","guid":{"rendered":"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/"},"modified":"2022-10-03T11:19:15","modified_gmt":"2022-10-03T09:19:15","slug":"therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients","status":"publish","type":"pillole-di-scienza","link":"https:\/\/www.agingproject.uniupo.it\/en\/health-professionals\/science-pills\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/","title":{"rendered":"Therapy with new oral anticoagulant drugs is effective in treating atrial fibrillation in elderly patients"},"content":{"rendered":"

Reference<\/strong><\/h3>\n

Malik AH, Yandrapalli S, ET AL. Meta-Analysis of Direct-Acting Oral Anticoagulants Compared with Warfarin in Patients >75 Years of Age<\/a>. Am J Cardiol. 2019;123(12):2051-2057. doi:10.1016\/j.amjcard.2019.02.060<\/p>\n

At a glance<\/strong><\/h3>\n

A study published in the American Journal of Cardiology<\/em> showed that in elderly people with atrial fibrillation<\/strong><\/a>, therapy with the new oral anticoagulant drugs<\/strong> (DOACs or NOACs) has superior efficacy in reducing stroke<\/a> (as well as systemic embolization in general) when compared with standard warfarin-based anticoagulant therapy (VKA)<\/strong>. Moreover, in addition to being effective, DOACs<\/strong> also have a good safety profile. Compared with VKA<\/strong>, DOACs have a similar rate of major bleeding but a significantly lower rate of intracranial hemorrhage \u2013 the most feared complication.<\/p>\n

What is already known<\/b><\/h3>\n

We know that:<\/span><\/p>\n

    \n
  • \n
      \n
    • Atrial fibrillation<\/b> (AF) is a frequent condition in the elderly population. In fact, it is the most common <\/span>arrhythmia<\/b> (i.e., presence of irregular heart rhythm) in these individuals: <\/span>as many as 10% of people over 75 years of age are affected<\/b>;<\/span><\/li>\n
    • AF is conventionally divided into valvular or nonvalvular. There is no satisfactory or uniform definition for these two terms. The term <\/span>valvular AF<\/b> is related to rheumatic valvular disease (predominantly mitral stenosis) or the presence of mechanical heart valve prostheses; all other cases will fall into the much more common condition of <\/span>nonvalvular AF (NVAF)<\/b>;<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n
        \n
      • All types of<\/span> AF<\/b> are associated with an approximately five times greater <\/span>risk of stroke<\/b> in patients who have it when compared to those who do not. For this reason, it is essential to adopt proper thrombo-embolic <\/span>risk prevention strategies<\/b>, the cornerstone of which is <\/span>oral anticoagulant therapy<\/b>;<\/span><\/li>\n<\/ul>\n
          \n
        • Until the discovery of DOACs a few years ago, the only drugs available for the anticoagulant treatment of patients with AF were the <\/span>vitamin K antagonist drugs<\/b> (so-called VKAs, of which warfarin is the earliest example). These VKAs, despite limitations related to pharmacokinetics, bioavailability, and therapeutic range maintenance, have been the drugs of choice;<\/span><\/li>\n
        • In recent years, the range of possible <\/span>therapeutic strategies<\/b> has been greatly strengthened by the addition of <\/span>DOACs<\/b>. DOACs have entirely different mechanisms of action from <\/span>VKAs<\/b> and have demonstrated good efficacy and safety, at least for the condition of <\/span>NVAF<\/b>. Until now, however, it had not been possible to extrapolate the results of randomized clinical trials to all real-world patients, and specifically to the subgroup of elderly patients.<\/span><\/li>\n<\/ul>\n

           <\/p>\n

          Design and Methods<\/b><\/h3>\n

          This <\/span>meta-analysis<\/b> included <\/span>five randomized controlled trials<\/b> that aimed to compare <\/span>DOAC-based therapies <\/b>(4 drugs evaluated: apixaban, dabigatran, rivaroxaban, edoxaban)<\/span> or warfarin<\/b> in the <\/span>prevention of thromboembolic disease from NVAF. <\/b>The analysis focused only on elderly patients (in this case defined as being over 75 years old) and involved 28,000 recruited subjects. Results were analyzed with respect to each of the <\/span>two types of treatment regimens<\/b>, both in terms of <\/span>efficacy <\/b>(defined by the reduction of stroke and systemic embolism) and<\/span> safety <\/b>(defined by the prevalence of major bleeding events and\/or cerebral hemorrhages).<\/span>
          \n<\/span><\/p>\n

          Main Findings<\/b><\/h3>\n

          DOAC<\/b> treatment of these subjects recruited with <\/span>NVAF<\/b> was associated with a <\/span>better benefit\/risk ratio<\/b> than those treated with <\/span>warfarin<\/b>, in particular:<\/span><\/p>\n

           <\/p>\n

            \n
          • DOACs<\/b> as a group have higher efficacy than <\/span>warfarin <\/b>in reducing <\/span>stroke <\/b>or <\/span>systemic embolization<\/b> (hazard ratio HR 0.76, 95% confidence interval 0.67-0.86, p< 0.01);<\/span><\/li>\n
          • The overall rate of major bleedings was similar between DOACs and<\/b> VKAs, but there were far fewer <\/span>intracranial hemorrhages<\/b> in patients randomized to a DOAC (HR 0.48, 95% confidence interval 0.34-0.67, p< 0.01) with the only exception of rivaroxaban;<\/span><\/li>\n
          • Apixaban was the only DOAC to significantly reduce all the three major adverse events tested in the study compared with warfarin<\/b> (i.e., systemic embolization, major bleeding, and intracranial hemorrhage), respectively by 29%, 36% and 66%.<\/span><\/li>\n<\/ul>\n

             <\/p>\n

            In summary, <\/span>DOACs<\/b> were found to be safer and <\/span>more effective than traditional warfarin therapy<\/b> for the treatment of NVAF<\/b> in the older patient subgroup. Although this is a class effect, amongst DOACs apixaban is the drug that appears to provide the best combination of efficacy and safety in this population.<\/span><\/p>\n

            Limitations<\/b><\/h3>\n

            The main limitation of this study is the <\/span>absence of trials<\/b> with head-to-head comparisons between the different <\/span>DOACs<\/b>. All comparisons between the DOACs can therefore only be indirect. However, it should be be kept in mind that it is extremely unlikely that direct comparisons will be made in the near future.\u00a0<\/span><\/p>\n

            Other possible limitations that require caution when comparing the different studies include:<\/span><\/p>\n

              \n
            • The fact that one of the trials included in the meta-analysis used an open-label design (i.e., in which information is not hidden to study participants), unlike the other 4 studies;<\/span><\/li>\n
            • the fact that dabigatran has a slightly different mechanism of action than the other tested DOACs;<\/span><\/li>\n
            • the lack of important details on demographics and comorbidities in some studies.<\/span><\/li>\n<\/ul>\n

               <\/p>\n

              What\u2019s New<\/b><\/h3>\n

              The most interesting aspect of this research is that it confirms, for the first time, the <\/span>notable efficacy and safety profile of DOACs<\/b>, even in subgroups of <\/span>patients with<\/b> extremely fragile AF<\/b>, such as older individuals. Specifically, <\/span>DOACs have been shown not to be inferior to warfarin<\/b> in the prevention of stroke\/systemic embolism, with a clearly better safety profile on intracranial hemorrhage<\/b> (the most feared complication of anticoagulation).<\/span>
              \n<\/span>
              \n<\/span>In practical terms, this new information on the use of <\/span>DOACs<\/b> in <\/span>elderly patients<\/b> also suggests the possibility of future therapeutic improvements. Until now, despite its well-established efficacy in stroke prevention, <\/span>standard warfarin therapy has always been substantially underutilized in this age group<\/b>, mainly because of a perceived increased risk of bleeding. <\/span>Increasing age also complicates this <\/b>issue, with additional difficulties related to poor adherence, cognitive impairment, risk of falls, drug interactions, and polypharmacy. In this sense, although still not risk-free, <\/span>DOACs<\/b> appear very promising. They can be administered by mouth, are characterized by rapid onset and cessation of effects, reveal a low presence of dietary and drug interactions, and lack the need for routine monitoring.<\/span><\/p>\n

              What are the prospects<\/b><\/h3>\n
                \n
              • Regarding research possibilities, the<\/span> results obtained from this study suggest the need for future ad-hoc confirmatory studies that are dedicated only to older AF patients from the start. <\/b>Although this <\/span>meta-analysis<\/b> is based exclusively on <\/span>randomized controlled clinical trials<\/b>, it is still a <\/span>post hoc<\/span><\/i> subgroup analysis, and therefore the results obtained so far should be considered a “hypothesis-generating” study;<\/span><\/li>\n
              • As mentioned earlier, it would also be desirable for studies dedicated to <\/span>direct comparisons of the various DOACs in those elderly patients with AF<\/b> be started soon. Although currently supported by online indirect evidence and requiring confirmation, the finding that <\/span>apixaban<\/b> is likely to be more cost-effective than the other commercially available DOACs seems important. Finally, <\/span>DOACs indeed remain more expensive than warfarin<\/b>. It therefore seems crucial to always consider the cost associated with these new therapies and choose those with the best pharmacoeconomic profile (including the costs attributable to adverse events).<\/span><\/li>\n<\/ul>\n

                 <\/p>\n

                By Carlo Smirne<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

                A study published in American Journal of Cardiology showed that in elderly people with atrial fibrillation, therapy with the new oral anticoagulant drugs has superior efficacy compared with standard warfarin-based anticoagulant therapy <\/p>\n","protected":false},"featured_media":11654,"template":"","tipo-pillola":[2272],"argomento-pillole":[5039],"class_list":["post-11797","pillole-di-scienza","type-pillole-di-scienza","status-publish","has-post-thumbnail","hentry","tipo-pillola-aging-related-diseases","argomento-pillole-pharmacology"],"yoast_head":"\nNew oral anticoagulant drugs in the treatment of atrial fibrillation<\/title>\n<meta name=\"description\" content=\"Study showed therapy with new oral anticoagulant drugs has superior efficacy compared with standard anticoagulant therapy\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Therapy with new oral anticoagulant drugs is effective in treating atrial fibrillation in elderly patients\" \/>\n<meta property=\"og:description\" content=\"Study showed therapy with new oral anticoagulant drugs has superior efficacy compared with standard anticoagulant therapy\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Aging Project Uniupo\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-03T09:19:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.agingproject.uniupo.it\/wp-content\/uploads\/2022\/08\/photo-1587370560942-ad2a04eabb6d.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1170\" \/>\n\t<meta property=\"og:image:height\" content=\"780\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ProjectAging\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/\",\"url\":\"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/\",\"name\":\"New oral anticoagulant drugs in the treatment of atrial fibrillation\",\"isPartOf\":{\"@id\":\"https:\/\/www.agingproject.uniupo.it\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.agingproject.uniupo.it\/wp-content\/uploads\/2022\/08\/photo-1587370560942-ad2a04eabb6d.webp\",\"datePublished\":\"2022-09-07T09:31:03+00:00\",\"dateModified\":\"2022-10-03T09:19:15+00:00\",\"description\":\"Study showed therapy with new oral anticoagulant drugs has superior efficacy compared with standard anticoagulant therapy\",\"breadcrumb\":{\"@id\":\"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/#primaryimage\",\"url\":\"https:\/\/www.agingproject.uniupo.it\/wp-content\/uploads\/2022\/08\/photo-1587370560942-ad2a04eabb6d.webp\",\"contentUrl\":\"https:\/\/www.agingproject.uniupo.it\/wp-content\/uploads\/2022\/08\/photo-1587370560942-ad2a04eabb6d.webp\",\"width\":1170,\"height\":780,\"caption\":\"oral anticoagulant drugs\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.agingproject.uniupo.it\/homepage\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"pillole di scienza\",\"item\":\"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Therapy with new oral anticoagulant drugs is effective in treating atrial fibrillation in elderly patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.agingproject.uniupo.it\/#website\",\"url\":\"https:\/\/www.agingproject.uniupo.it\/\",\"name\":\"Aging Project Uniupo\",\"description\":\"Facing the challenge of longevity, through interdisciplinary research\",\"publisher\":{\"@id\":\"https:\/\/www.agingproject.uniupo.it\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.agingproject.uniupo.it\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.agingproject.uniupo.it\/#organization\",\"name\":\"Aging Project - DIMET - Universit\u00e0 del Piemonte Orientale\",\"url\":\"https:\/\/www.agingproject.uniupo.it\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.agingproject.uniupo.it\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.agingproject.uniupo.it\/wp-content\/uploads\/2019\/12\/logo-upo-orizzontale.png\",\"contentUrl\":\"https:\/\/www.agingproject.uniupo.it\/wp-content\/uploads\/2019\/12\/logo-upo-orizzontale.png\",\"width\":622,\"height\":213,\"caption\":\"Aging Project - DIMET - Universit\u00e0 del Piemonte Orientale\"},\"image\":{\"@id\":\"https:\/\/www.agingproject.uniupo.it\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/ProjectAging\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"New oral anticoagulant drugs in the treatment of atrial fibrillation","description":"Study showed therapy with new oral anticoagulant drugs has superior efficacy compared with standard anticoagulant therapy","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/","og_locale":"en_US","og_type":"article","og_title":"Therapy with new oral anticoagulant drugs is effective in treating atrial fibrillation in elderly patients","og_description":"Study showed therapy with new oral anticoagulant drugs has superior efficacy compared with standard anticoagulant therapy","og_url":"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/","og_site_name":"Aging Project Uniupo","article_modified_time":"2022-10-03T09:19:15+00:00","og_image":[{"width":1170,"height":780,"url":"https:\/\/www.agingproject.uniupo.it\/wp-content\/uploads\/2022\/08\/photo-1587370560942-ad2a04eabb6d.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_site":"@ProjectAging","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/","url":"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/","name":"New oral anticoagulant drugs in the treatment of atrial fibrillation","isPartOf":{"@id":"https:\/\/www.agingproject.uniupo.it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/www.agingproject.uniupo.it\/wp-content\/uploads\/2022\/08\/photo-1587370560942-ad2a04eabb6d.webp","datePublished":"2022-09-07T09:31:03+00:00","dateModified":"2022-10-03T09:19:15+00:00","description":"Study showed therapy with new oral anticoagulant drugs has superior efficacy compared with standard anticoagulant therapy","breadcrumb":{"@id":"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/#primaryimage","url":"https:\/\/www.agingproject.uniupo.it\/wp-content\/uploads\/2022\/08\/photo-1587370560942-ad2a04eabb6d.webp","contentUrl":"https:\/\/www.agingproject.uniupo.it\/wp-content\/uploads\/2022\/08\/photo-1587370560942-ad2a04eabb6d.webp","width":1170,"height":780,"caption":"oral anticoagulant drugs"},{"@type":"BreadcrumbList","@id":"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/therapy-with-new-oral-anticoagulantdrugs-is-effective-in-treating-atrial-fibrillation-in-elderly-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.agingproject.uniupo.it\/homepage\/"},{"@type":"ListItem","position":2,"name":"pillole di scienza","item":"https:\/\/www.agingproject.uniupo.it\/per-i-professionisti\/pillole-di-scienza\/"},{"@type":"ListItem","position":3,"name":"Therapy with new oral anticoagulant drugs is effective in treating atrial fibrillation in elderly patients"}]},{"@type":"WebSite","@id":"https:\/\/www.agingproject.uniupo.it\/#website","url":"https:\/\/www.agingproject.uniupo.it\/","name":"Aging Project Uniupo","description":"Facing the challenge of longevity, through interdisciplinary research","publisher":{"@id":"https:\/\/www.agingproject.uniupo.it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.agingproject.uniupo.it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.agingproject.uniupo.it\/#organization","name":"Aging Project - DIMET - Universit\u00e0 del Piemonte Orientale","url":"https:\/\/www.agingproject.uniupo.it\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.agingproject.uniupo.it\/#\/schema\/logo\/image\/","url":"https:\/\/www.agingproject.uniupo.it\/wp-content\/uploads\/2019\/12\/logo-upo-orizzontale.png","contentUrl":"https:\/\/www.agingproject.uniupo.it\/wp-content\/uploads\/2019\/12\/logo-upo-orizzontale.png","width":622,"height":213,"caption":"Aging Project - DIMET - Universit\u00e0 del Piemonte Orientale"},"image":{"@id":"https:\/\/www.agingproject.uniupo.it\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ProjectAging"]}]}},"_links":{"self":[{"href":"https:\/\/www.agingproject.uniupo.it\/en\/wp-json\/wp\/v2\/pillole-di-scienza\/11797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.agingproject.uniupo.it\/en\/wp-json\/wp\/v2\/pillole-di-scienza"}],"about":[{"href":"https:\/\/www.agingproject.uniupo.it\/en\/wp-json\/wp\/v2\/types\/pillole-di-scienza"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.agingproject.uniupo.it\/en\/wp-json\/wp\/v2\/media\/11654"}],"wp:attachment":[{"href":"https:\/\/www.agingproject.uniupo.it\/en\/wp-json\/wp\/v2\/media?parent=11797"}],"wp:term":[{"taxonomy":"tipo-pillola","embeddable":true,"href":"https:\/\/www.agingproject.uniupo.it\/en\/wp-json\/wp\/v2\/tipo-pillola?post=11797"},{"taxonomy":"argomento-pillole","embeddable":true,"href":"https:\/\/www.agingproject.uniupo.it\/en\/wp-json\/wp\/v2\/argomento-pillole?post=11797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}